Skip to main contentFREE SHIPPING THRESHOLD$250 REMAINING
MK-IV SPEC
LAT: 34.0522° NLONG: 118.2437° W
RESEARCH ONLYOA-933-CAG
Cagrilintide
Long-Acting Amylin
UNIT COST$58.00
STATUSIN STOCK
SELECT MASS (MG)
QTY
1
MISSION CRITICAL: For in vitro laboratory research only. Not for human or veterinary use. Not evaluated by the FDA. Must be 21+.
SPECIFICATIONS
CAS No.1415456-99-3
Mol. Weight4409.01 g/mol
Purity≥99.0% (HPLC)
FormLyophilized Powder
Storage−20°C · Lyophilized
Mol. FormulaC194H312N54O59S2
COMPOUND INTEL
REF #OA-933-CAGMECHANISM_DUMP
MOLECULAR PROFILE
Cagrilintide is a long-acting amylin analog with a fatty acid side chain. With the molecular formula C₁₉₀H₂₉₇N₅₁O₅₈ and a molecular weight of 4220.8 g/mol (CAS: 1417329-69-3), it structurally mimics endogenous peptides while extending its sequence.
AMINO ACID SEQUENCE
Long-acting amylin analogueLong-Acting AmylinAmylin Receptors (AMY)Calcitonin Receptors
MECHANISM OF ACTION
Amylin Receptors (AMY)Receptor interaction
Published research demonstrates Cagrilintide modulates targeted signaling cascades within cell tissue models (PMID: 41702251).
Calcitonin ReceptorsSignaling cascade
In cellular environments, Cagrilintide exhibits selective binding and corresponding pathway activation (PMID: 41109426).
TECHNICAL DATA
- CAS No.
- 1415456-99-3
- Mol. Formula
- C194H312N54O59S2
- Mol. Weight
- 4409.01 g/mol
- Purity
- ≥99.0% (HPLC)
- Form
- Lyophilized Powder
- Storage
- −20°C · Lyophilized
PMID REFERENCE LIBRARY
PMID: 41702251
Alhalabi et al. (2026) investigated Cagrilintide's binding affinity and receptor interactions in vitro (PMID: 41702251).
Alhalabi H, et al. (2026). In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research. J Pharm Biomed Anal.PMID: 41109426Briere et al. (2025) investigated Cagrilintide's binding affinity and receptor interactions in vitro (PMID: 41109426).
Briere DA, et al. (2025). Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab.
